2C-B-morpholine, also known as 2C-B-norphenmetrazine or as 2-(4-bromo-2,5-dimethoxyphenyl)morpholine, is a serotonin receptor modulator of the phenylmorpholine (phenmetrazine) and cyclized phenethylamine groups.[1] It is a ligand of the serotonin 5-HT2A receptor, with an affinity of 20.6 nM and an Emax of 4%.[1] The drug showed 103-fold lower affinity for this receptor than R(–)-DOB and had minimal agonist activity (with R(–)-DOB having an Emax of 51% in the assay), so for practical purposes would act as an antagonist at the 5-HT2A receptor under most circumstances, despite being technically classified as a partial agonist.[1] 2C-B-morpholine was first described in the scientific literature by Richard Glennon and colleagues by 2004.[1]
 | |
| Clinical data | |
|---|---|
| Other names | 2C-B-Norphenmetrazine; 2-(4-Bromo-2,5-dimethoxyphenyl)morpholine; 2C-B-MOR; 2C-B-Mor |
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor ligand |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C12H16BrNO3 |
| Molar mass | 302.168 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
See also
editReferences
edit- 1 2 3 4 Glennon RA, Bondarev ML, Khorana N, Young R, May JA, Hellberg MR, et al. (November 2004). "Beta-oxygenated analogues of the 5-HT2A serotonin receptor agonist 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane". Journal of Medicinal Chemistry. 47 (24): 6034–6041. doi:10.1021/jm040082s. PMID 15537358.
One of the first compounds prepared and examined in this investigation was morpholine analogue 2. Compound 2 bears an ether oxygen atom at the benzylic position that is tethered to the terminal amine. However, its 5-HT2A affinity (Ki) 20.6 nM) is 100-fold lower than that of R(-)DOB (Ki) 0.2 nM), and its agonist efficacy in the 5-HT2-mediated calcium mobilization assay is minimal (Table 1). There are several possible explanations for these unfavorable findings. Apart from the molecule possessing a chiral center, the ether oxygen atom might not be tolerated by the receptor and/or the added ethylene "bridge" might not be readily accommodated by the receptor and its presence detracts from affinity. A more plausible explanation, based on prior structure-affinity investigations, is that the secondary amine of 2 contributes to decreased affinity. That is, we have previously shown that addition of small N-alkyl substituents can reduce the 5-HT2A receptor affinity of DOB and DOB-related compounds.16,17
External links
edit
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information. |